Investing.com — Fortrea Holdings Inc.在充满挑战的市场环境中，其股价触及52周低点，跌至8.15美元。根据 InvestingPro 数据显示，这一价格较52周高点40.63美元大幅下跌，不过技术指标表明该股目前处于超卖区域。这一最新价格水平反映了该公司的显著下滑，其股价在过去一年中已下跌了79.45%。投资者一直密切关注Fortrea Holdings，因为该 ...

Fortrea Holdings Inc.（纳斯达克代码：FTRE）首席运营官Mark A. Morais近期出售了该公司价值4,980美元的普通股。这家市值约8.95亿美元的临床研究机构的股票交易发生在2025年3月12日，平均售价为9.98美元，接近该股52周低点9.55美元。根据 InvestingPro ...

NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Fortrea Holdings Inc. has a one year low of $8.16 and a one year high of $40.63. Fortrea ( NASDAQ:FTRE – Get Free Report ) last issued its quarterly earnings results on Monday, March 3rd.

William Blair：重申Fortrea Holdings(FTRE.US)评级，由大市一致调整至大市一致评级。 Fortrea Holdings（FTRE.US）公司简介：Fortrea Holdings是一家后期合同研究组织 ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year ...

Fitch predicts a 7.3% decline in Fortrea’s revenues in 2025 and expects revenue growth to return in 2026 within the 3.0% to 4.0% range. The company’s inconsistent revenue growth and uncertain ...

Fortrea Holdings Inc. ( (FTRE)) has released its Q4 earnings. Here is a breakdown of the information Fortrea Holdings Inc. presented to its investors. Discover the Best Stocks and Maximize Your ...

Fortrea Holdings Inc. (NASDAQ:FTRE) Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.36.

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports.

Ladies and gentlemen, thank you for standing by, and welcome to Fortrea Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being ...

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.